Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) ended Friday session in red amid volatile trading. The shares closed down -0.27 points or -0.53% at $50.23 with 1.78 million shares getting traded. Post opening the session at $50.24, the shares hit an intraday low of $49.68 and an intraday high of $51.31 and the price vacillated in this range throughout the day. The company has a market cap of $7.02 billion and the numbers of outstanding shares have been calculated to be 140.52 million shares.
Seattle Genetics, Inc. (SGEN) announced that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.
Shares of Akorn, Inc. (NASDAQ:AKRX) ended Friday session in red amid volatile trading. The shares closed down -0.09 points or -0.33% at $27.27 with 1.73 million shares getting traded. Post opening the session at $27.10, the shares hit an intraday low of $27.10 and an intraday high of $28.04 and the price vacillated in this range throughout the day. The company has a market cap of $3.43 billion and the numbers of outstanding shares have been calculated to be 126.03 million shares.
Akorn, Inc. (AKRX) on Aug. 25, 2016 announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use.
About Ofloxacin Otic Solution
Ofloxacin Otic Solution is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:
- Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus.
- Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus.
- Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
According to IMS Health, sales of Ofloxacin Otic Solution were approximately $33 million for the twelve months ended June 30, 2016.